The Kanagawa Cancer Center is a comprehensive cancer center in Yokohama, Japan. The Cancer Center which consists of research institute and hospital is now an ancillary establishment of Kanagawa Prefectural Hospital Organization. In 2015, I-ROCK in the Cancer Center will be open as a new Heavy-ion treatment center.

There are 415 beds in Kanagawa Cancer Center.

During the past decade, Kanagawa Cancer Center conducted 30 clinical trials. In the 10-year time frame, 30 clinical trials started and 8 clinical trials were completed, i.e. on average, 26.7% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 7 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kanagawa Cancer Center" #1 sponsor was "Hoffmann-La Roche" with 20 trials, followed by "Daiichi Sankyo, Inc." with 4 trials sponsored, "Haruhiko Fukuda" with 4 trials sponsored, "Japan Clinical Oncology Group" with 4 trials sponsored and "Janssen Research & Development, LLC" with 4 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kanagawa Cancer Center" #1 collaborator was "Ministry of Health, Labour and Welfare, Japan" with 8 trials as a collaborator, "AstraZeneca" with 4 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 3 trials as a collaborator, "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator and "Breast International Group" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Kanagawa Cancer Center" are "Breast Cancer" (7 trials), "Carcinoma, Non-Small-Cell Lung" (3 trials), "Non-Small Cell Lung Cancer" (3 trials), "Carcinoma, Hepatocellular" (2 trials) and "Gastric Neoplasm" (2 trials). Many other conditions were trialed in "Kanagawa Cancer Center" in a lesser frequency.

Most popular intervention types in "Kanagawa Cancer Center" are "Drug" (37 trials), "Procedure" (5 trials), "Other" (2 trials), "Device" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (11 trials), "Paclitaxel" (7 trials), "Cisplatin" (6 trials), "Gemcitabine" (6 trials) and "Pemetrexed" (6 trials). Other intervention names were less common.

The vast majority of trials in "Kanagawa Cancer Center" are 39 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Kanagawa Cancer Center". undefined are not yet recruiting, 9 are recruiting, 13 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in Kanagawa Cancer Center, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Kanagawa Cancer Center, 5 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 31 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".